MDT Yahoo Finance notes analysts’ consensus price target at $91, implying around 9% upside from current levels. The forecast factors in recovery in elective procedures and ongoing product innovation. In July, Boston Scientific announced its second-quarter 2023 results, wherein it registered a strong year-over-year improvement in organic sales, indicating a solid rebound in the legacy business even amid several macroeconomic issues. BSX’s revenues from its Cardiovascular segment and sub-segments (Cardiology and Peripheral Interventions) were also strong. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Medtronic is currently sporting a Zacks Rank of #3 (Hold). MDT Yahoo Finance shows Medtronic’s 52-week range between $68.84 and $92.05, indicating significant volatility over the past year. Technical traders watch for support levels near $80 and resistance near $85 to gauge short-term breakout potential in the medical devices space.